A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma

Phase 2 Unknown 130 enrolled Nanjing Sanhome Pharmaceutical, Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of SHC014748M in patients with relapsed or refractory relapsed or refractory Peripheral T Cell Lymphoma.

Timeline

Start: 2020-08
Primary completion: 2021-05
Completion: 2021-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHC014748M	Unknown	200 mg	Oral

A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma

Summary

Timeline

Drugs

Indications